• linkedin
  • Increase Font
  • Sharebar

    Cisplatin nanoparticles appear efficacious for treating NMIBC


    And when they administered both drugs to rats with bladder cancer, the nanoparticle delivery resulted in six times the drug concentration in the rats’ bladders 1 hour post treatment and 10 times more drug in the bladder 4 hours after treatment, compared with animals in the regular cisplatin group.

    The rats treated with the cisplatin nanoparticles were the only treatment group at 16 weeks to have no evidence of invasive carcinoma. One-fifth or more of the rats treated with regular cisplatin and half of those given no treatment had evidence of high-grade tumors at 4 months.

    The findings suggest that by using the nanoparticle drug delivery approach, urologists and other clinicians treating nonmuscle-invasive bladder cancer patients might eventually have a nonsurgical option for those who fail first-line bacillus Calmette-Guérin (BCG) therapy, according to Dr. Kates, lead author of the paper and one of the owners of a related patent.

    “There’s a lot of new interest in chemotherapy, as we begin to sequence bladder tumors—especially early-stage bladder tumors,” Dr. Kates said.

    Read: Two-drug therapy for advanced UC shows superior PFS

    “We know that not all bladder tumors respond to BCG. Increasingly, we’re going to be identifying the genetics of a patient’s bladder tumor and, hopefully, will know in the future whether the patient will respond to BCG or not. There’s a large space for drugs like this that can help treat patients with nonmuscle-invasive bladder cancer,” added Dr. Kates, who worked on the study with Trinity Bivalacqua, MD, PhD, and colleagues.

    Delivery of nanoparticle chemotherapy has been used in other cancer types in which the drug has to get across a hostile barrier in the body, such as across vaginal or eye mucosa, according to Dr. Kates.

    Dr. Kates said that while these were animal model studies and the approach has not yet been proven in humans, the animal model used has been validated as being reflective of human bladder cancer.

    “We are continuing to perform validation studies and pursuing early-phase trials this year,” he said.

    Five of the study authors own a patent related to this project. Funding for the study was provided by The Greenberg Bladder Cancer Institute and the Urology Care Foundation.

    More from Urology Times:

    Better models needed for predicting bladder Ca recurrence

    Investigational BCG-refractory NMIBC Tx shows promise

    Bladder Ca photothermal treatment yields encouraging results

    To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.

    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results